Effect of hypericum perforatum in obesity

Phase 3

Recruiting

• Conditions: Obesity.; Obesity due to excess calories

• Registration Number: IRCT20110809007265N12
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 July 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

BMI 24.9 to 39.9
Women 18 years to premenopausal and men 18 to 60 years old
Consent to participate in the study
History of at least one monotherapy failure

Exclusion Criteria

Hypothyroidism, Cushing's syndrome, cancer, liver or kidney failure
Psychiatric disorders associated with eating like anorexia nervosa and hyperorexia
Using drugs effective on weight and metabolism in the previous month
Using drugs that interfere with Hypericum perforatum such as protease inhibitors, amiodarone, anticoagulants, cyclophosphamide, cyclosporine, monoamine oxidase inhibitors, phenytoin, tacrolimus, tamoxifen and trazodone drug
Drug abuser or alcoholism
Breast-feeding, pregnancy or planning a pregnancy during the next two months
Pacemaker and any metal device inside the body due to the use of Bioelectrical Impedance Analyzer
Disability to do recommended physical activity
Allergy to hypericum perforatum

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Appetite. Timepoint: Before intervention, week 3, week 6. Method of measurement: Visual Analogue Scale.;Body weight. Timepoint: Before intervention, week 3, week 6. Method of measurement: Kilogram.;Waist to hip ratio. Timepoint: Before intervention, week 3, week 6. Method of measurement: Centimeter.

Secondary Outcome Measures

Name	Time	Method
Insulin. Timepoint: Before intervention, after intervention. Method of measurement: IU.;Fasting Blood Sugar. Timepoint: Before intervention, after intervention. Method of measurement: Mg/dl.